Efficacy of cabazitaxel in fourth or later line of therapy in metastatic castration-resistant prostate cancer: Multi-institutional real-world experience in Germany-Reference-Cited by-同舟云学术

Efficacy of cabazitaxel in fourth or later line of therapy in metastatic castration-resistant prostate cancer: Multi-institutional real-world experience in Germany

Published:2022-12 Issue:12 Volume:40 Page:538.e7-538.e14
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Wenzel Mike^ORCID,Borkowetz Angelika,Lieb Verena,Hoffmann Manuela A.,Borgmann Hendrik,Höfner Thomas,Dotzauer Robert,Neuberger Manuel,Worst Thomas S.,von Hardenberg Jost,Linxweiler Johannes,Klümper Niklas

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference21 articles.

1. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology;Mohler;J Natl Compr Cancer Netw JNCCN,2019

2. Mottet N, Cornford P, Van den Bergh RCN et al. EAU - EANM - ESTRO - ESUR - SIOG. Guidelines on prostate cancer. Published online 2020.

3. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis;Wenzel;Prostate Cancer Prostatic Dis,2022

4. Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis;Mori;Prostate Cancer Prostatic Dis,2020

5. Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: systematic review and network meta-analysis;Wenzel;Eur Urol Focus,2022

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contemporary Treatment Patterns and Oncological Outcomes of Metastatic Hormone-sensitive Prostate Cancer and First- to Sixth- line Metastatic Castration-resistant Prostate Cancer Patients;European Urology Open Science;2024-08

2. Prostate-specific Antigen Nadir and Cancer-Control Outcomes in Real-world Apalutamide-treated Metastatic Hormone-Sensitive Prostate Cancer Patients: A Single-Center Analysis;European Urology Oncology;2024-08

3. Prostatakarzinom;Therapie-Handbuch - Onkologie und Hämatologie;2024